From research to regulation, the biotech industry is taking a hit, but drug-development companies continue to press forward, moving important discoveries from the lab bench to the patient bedside. The program will begin with a talk with Ultragenyx CEO Emil Kakkis, the scientist behind the first treatment for an ultra-rare genetic disease, and Ryan Dant, the...
What You’ll Learn: Gain insights into how renewed leasing activity, selective capital and improving absorption are reshaping demand, investment, and development decisions across the Bay Area life sciences market. Learn how owners, developers, and operators are rethinking space utilization, right sizing portfolios, and repositioning existing assets to meet today’s tenant expectations. Examine why South San...
